195 related articles for article (PubMed ID: 36251745)
1. Distinct clonal identities of B-ALLs arising after lenolidomide therapy for multiple myeloma.
Barnell EK; Skidmore ZL; Newcomer KF; Chavez M; Campbell KM; Cotto KC; Spies NC; Ruzinova MB; Wang T; Abro B; Kreisel F; Parikh BA; Duncavage EJ; Frater JL; Lee YS; Hassan A; King JA; Kohnen DR; Fiala MA; Welch JS; Uy GL; Vij K; Vij R; Griffith M; Griffith OL; Wartman LD
Blood Adv; 2023 Jan; 7(2):236-245. PubMed ID: 36251745
[TBL] [Abstract][Full Text] [Related]
2. Molecular characteristics of terminal deoxynucleotidyl transferase negative precursor B-cell phenotype Burkitt leukemia with IGH-MYC rearrangement.
Yoon J; Yun JW; Jung CW; Ju HY; Koo HH; Kim SH; Kim HJ
Genes Chromosomes Cancer; 2020 Apr; 59(4):255-260. PubMed ID: 31705772
[TBL] [Abstract][Full Text] [Related]
3. Lenalidomide-Associated Secondary B-Lymphoblastic Leukemia/Lymphoma-A Unique Entity.
Germans SK; Kulak O; Koduru P; Oliver D; Gagan J; Patel P; Anderson LD; Fuda FS; Chen W; Jaso JM
Am J Clin Pathol; 2020 Nov; 154(6):816-827. PubMed ID: 32880627
[TBL] [Abstract][Full Text] [Related]
4. B-cell acute lymphoblastic leukemia in an elderly man with plasma cell myeloma and long-term exposure to thalidomide and lenalidomide: a case report and literature review.
Sinit RB; Hwang DG; Vishnu P; Peterson JF; Aboulafia DM
BMC Cancer; 2019 Nov; 19(1):1147. PubMed ID: 31775673
[TBL] [Abstract][Full Text] [Related]
5. Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma.
Ching T; Duncan ME; Newman-Eerkes T; McWhorter MME; Tracy JM; Steen MS; Brown RP; Venkatasubbarao S; Akers NK; Vignali M; Moorhead ME; Watson D; Emerson RO; Mann TP; Cimler BM; Swatkowski PL; Kirsch IR; Sang C; Robins HS; Howie B; Sherwood A
BMC Cancer; 2020 Jun; 20(1):612. PubMed ID: 32605647
[TBL] [Abstract][Full Text] [Related]
6. Analysis of Ig and T-cell receptor genes in 40 childhood acute lymphoblastic leukemias at diagnosis and subsequent relapse: implications for the detection of minimal residual disease by polymerase chain reaction analysis.
Beishuizen A; Verhoeven MA; van Wering ER; Hählen K; Hooijkaas H; van Dongen JJ
Blood; 1994 Apr; 83(8):2238-47. PubMed ID: 8161789
[TBL] [Abstract][Full Text] [Related]
7. Chronic lymphocytic leukemia patients with IGH translocations are characterized by a distinct genetic landscape with prognostic implications.
Pérez-Carretero C; Hernández-Sánchez M; González T; Quijada-Álamo M; Martín-Izquierdo M; Hernández-Sánchez JM; Vidal MJ; de Coca AG; Aguilar C; Vargas-Pabón M; Alonso S; Sierra M; Rubio-Martínez A; Dávila J; Díaz-Valdés JR; Queizán JA; Hernández-Rivas JÁ; Benito R; Rodríguez-Vicente AE; Hernández-Rivas JM
Int J Cancer; 2020 Nov; 147(10):2780-2792. PubMed ID: 32720348
[TBL] [Abstract][Full Text] [Related]
8. Massive evolution of the immunoglobulin heavy chain locus in children with B precursor acute lymphoblastic leukemia.
Gawad C; Pepin F; Carlton VE; Klinger M; Logan AC; Miklos DB; Faham M; Dahl G; Lacayo N
Blood; 2012 Nov; 120(22):4407-17. PubMed ID: 22932801
[TBL] [Abstract][Full Text] [Related]
9. A high frequency of circulating B cells share clonotypic Ig heavy-chain VDJ rearrangements with autologous bone marrow plasma cells in multiple myeloma, as measured by single-cell and in situ reverse transcriptase-polymerase chain reaction.
Szczepek AJ; Seeberger K; Wizniak J; Mant MJ; Belch AR; Pilarski LM
Blood; 1998 Oct; 92(8):2844-55. PubMed ID: 9763569
[TBL] [Abstract][Full Text] [Related]
10. Lymphocytic progenitor cell origin and clonal evolution of human B-lineage acute lymphoblastic leukemia.
Davi F; Gocke C; Smith S; Sklar J
Blood; 1996 Jul; 88(2):609-21. PubMed ID: 8695809
[TBL] [Abstract][Full Text] [Related]
11. Expression of CRBN, IKZF1, and IKZF3 does not predict lenalidomide sensitivity and mutations in the cereblon pathway are infrequent in multiple myeloma.
Dimopoulos K; Fibiger Munch-Petersen H; Winther Eskelund C; Dissing Sjö L; Ralfkiaer E; Gimsing P; Grønbaek K
Leuk Lymphoma; 2019 Jan; 60(1):180-188. PubMed ID: 29718735
[TBL] [Abstract][Full Text] [Related]
12. Stability and uniqueness of clonal immunoglobulin CDR3 sequences for MRD tracking in multiple myeloma.
Rustad EH; Misund K; Bernard E; Coward E; Yellapantula VD; Hultcrantz M; Ho C; Kazandjian D; Korde N; Mailankody S; Keats JJ; Akhlaghi T; Viny AD; Mayman DJ; Carroll K; Patel M; Famulare CA; Op Bruinink DH; Hutt K; Jacobsen A; Huang Y; Miller JE; Maura F; Papaemmanuil E; Waage A; Arcila ME; Landgren O
Am J Hematol; 2019 Dec; 94(12):1364-1373. PubMed ID: 31571261
[TBL] [Abstract][Full Text] [Related]
13. Oligoclonal immunoglobulin heavy-chain and T-cell receptor delta rearrangements persist in a recurrent acute lymphoblastic leukemia with one immunoglobulin kappa rearrangement as a clonal marker.
Stolz F; Panzer S; Fischer S; Panzer-Grümayer ER
Mod Pathol; 1999 Aug; 12(8):819-26. PubMed ID: 10463485
[TBL] [Abstract][Full Text] [Related]
14. Detection of Immunoglobulin Heavy Chain Gene Clonality by Next-Generation Sequencing for Minimal Residual Disease Monitoring in B-Lymphoblastic Leukemia.
Shin S; Hwang IS; Kim J; Lee KA; Lee ST; Choi JR
Ann Lab Med; 2017 Jul; 37(4):331-335. PubMed ID: 28445014
[TBL] [Abstract][Full Text] [Related]
15. Lenalidomide-associated B-cell ALL: clinical and pathologic correlates and sensitivity to lenalidomide withdrawal.
Geyer MB; Shaffer BC; Bhatnagar B; Mims AS; Klein V; Dilip D; Glass JL; Lozanski G; Hassoun H; Landau H; Zhang Y; Xiao W; Roshal M; Park JH
Blood Adv; 2023 Jul; 7(13):3087-3098. PubMed ID: 36827680
[TBL] [Abstract][Full Text] [Related]
16. B Lymphoblastic Leukemia/Lymphoma With Burkitt-like Morphology and IGH/MYC Rearrangement: Report of 3 Cases in Adult Patients.
Li Y; Gupta G; Molofsky A; Xie Y; Shihabi N; McCormick J; Jaffe ES
Am J Surg Pathol; 2018 Feb; 42(2):269-276. PubMed ID: 29112016
[TBL] [Abstract][Full Text] [Related]
17. TP53 and PTEN mutations were shared in concurrent germ cell tumor and acute megakaryoblastic leukemia.
Akizuki K; Sekine M; Kogure Y; Kameda T; Shide K; Koya J; Kamiunten A; Kubuki Y; Tahira Y; Hidaka T; Kiwaki T; Tanaka H; Sato Y; Kataoka H; Kataoka K; Shimoda K
BMC Cancer; 2020 Jan; 20(1):5. PubMed ID: 31898539
[TBL] [Abstract][Full Text] [Related]
18. Submicroscopic deletions of immunoglobulin heavy chain gene (IGH) in precursor B lymphoblastic leukemia with IGH rearrangements.
Huh J; Mun YC; Yoo ES; Seong CM; Chung WS
Ann Lab Med; 2015 Jan; 35(1):128-31. PubMed ID: 25553293
[TBL] [Abstract][Full Text] [Related]
19. Low relapse rate in children with acute lymphoblastic leukemia after risk-directed therapy.
Tzortzatou-Stathopoulou F; Papadopoulou AL; Moschovi M; Botsonis A; Tsangaris GT
J Pediatr Hematol Oncol; 2001 Dec; 23(9):591-7. PubMed ID: 11902303
[TBL] [Abstract][Full Text] [Related]
20. Metachronous/concomitant B-cell neoplasms with discordant light-chain or heavy-chain isotype restrictions: evidence of distinct B-cell neoplasms rather than clonal evolutions.
Wei Q; Sebastian S; Papavassiliou P; Rehder C; Wang E
Hum Pathol; 2014 Oct; 45(10):2063-76. PubMed ID: 25179408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
